The patient, if a main, is surgically sterile, or if capable of producing offspring, is currently using an approved method of birth control, and agrees to continued use of this method for the duration of the study (and for 60 days after taking the last dose of CEP-701 because of the possible effects on spermatogenesis). [clinicaltrials_resource:abdab849e70afb5a55066027a3f7256d]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
The patient, if a main, is surgically sterile, or if capable of producing offspring, is currently using an approved method of birth control, and agrees to continued use of this method for the duration of the study (and for 60 days after taking the last dose of CEP-701 because of the possible effects on spermatogenesis). [clinicaltrials_resource:abdab849e70afb5a55066027a3f7256d]
Bio2RDF identifier
abdab849e70afb5a55066027a3f7256d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:abdab849e70afb5a55066027a3f7256d
identifier
clinicaltrials_resource:abdab849e70afb5a55066027a3f7256d
title
The patient, if a main, is sur ...... e effects on spermatogenesis).
@en
type
label
The patient, if a main, is sur ...... ab849e70afb5a55066027a3f7256d]
@en